Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05553938
PHASE1

Effects of Acute and Chronic Empagliflozin Heart Failure

Sponsor: Yale University

View on ClinicalTrials.gov

Summary

This is a 60-patient randomized, double-blind, placebo-controlled mechanistic study to understand the utility of empagliflozin in worsening heart failure (HF) patients with or without diabetes. Participants will be randomized to empagliflozin or placebo for 6 weeks, followed by a crossover of placebo patients to active therapy at 6 weeks-12 weeks.

Official title: Renal Mechanistic Effects of Acute and Chronic Empagliflozin in Heart Failure

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2023-08-04

Completion Date

2025-11

Last Updated

2024-12-18

Healthy Volunteers

No

Conditions

Interventions

DRUG

Empagliflozin 10 mg

Empagliflozin 10mg

DRUG

Placebo

Empagliflozin matched placebo tablet

Locations (2)

Yale New Haven Hospital

New Haven, Connecticut, United States

Yale University

New Haven, Connecticut, United States